Financial Data and Key Metrics Changes - Total revenue for Q4 2025 reached $1.3 billion, representing a growth of 10.7% year-over-year, supported by a 16% increase in system-wide comparable sales [4] - Adjusted EBITDA for Q4 totaled $172.7 million, up 17.2% year-over-year, with an 80 basis points expansion in the adjusted EBITDA margin [4][12] - For the full year 2025, total revenue grew by almost 5% in US dollars, with adjusted EBITDA being the highest in the company's history [5][12] Business Line Data and Key Metrics Changes - In Brazil, comparable sales growth showed modest sequential improvement despite a challenging consumption environment, with a significant market share advantage maintained [9][10] - SLAD's comparable sales increased by 49.5% year-over-year, driven by strong execution in Argentina and other markets [11] - NOLAD experienced a 1.7% growth in comparable sales, with Mexico being the main contributor [10] Market Data and Key Metrics Changes - Digital channel penetration reached 62% of total sales, with digital channel sales growing 18.7% year-over-year [8] - The loyalty program had 27.2 million registered members at year-end, covering over 90% of all restaurants in the footprint [9] - The Brazilian real's strength contributed to revenue growth in US dollars during the quarter [10] Company Strategy and Development Direction - The company focuses on optimizing current business performance, maximizing returns on capital investments, and preparing for future business trends [3] - A disciplined approach to pricing, cost control, and marketing relevance has been emphasized, alongside investments in high-return restaurant development and digital capabilities [4] - The company plans to open 105-115 new restaurants in 2026, with total capital expenditures between $275 million and $325 million [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business momentum entering 2026, anticipating a more normalized consumer environment and continued profitability trends [21] - The company is focused on building healthy comparable sales while managing costs and maintaining market share [35] - Early results in 2026 have shown strong performance, with expectations for higher gross margins throughout the year [20] Other Important Information - The company opened 102 new restaurants in 2025, modernizing 73% of its portfolio by year-end [6] - A cash dividend of $0.28 per share has been declared for 2026, up from $0.24 the previous year [20] - The company implemented a G&A restructuring that reduced the ongoing cost base by more than $10 million annually [45] Q&A Session Summary Question: Can you explain the higher taxes paid during the quarter? - The effective tax rate for 2025 was 37.7%, an improvement of almost 5 percentage points versus 2024, with no structural changes expected for 2026 [26][27] Question: What are the drivers of margin expansion in Brazil and SLAD? - Brazil saw a small improvement in gross margin, with payroll expenses improving due to productivity gains, while SLAD experienced leverage in payroll and occupancy expenses [28][29] Question: Given the recent depreciation of LatAm currencies, how does this affect your outlook? - The Brazilian real and Mexican peso have appreciated, positively impacting results, with expectations for continued favorable currency performance [32][33] Question: How should we think about Brazil's comp sales throughout 2026? - The company expects to build healthy comparable sales, focusing on a combination of pricing and mix to offset volume declines [34] Question: Can you provide more details on the headcount reduction? - The G&A restructuring aimed to improve efficiency, resulting in a reduction of over $10 million in the annual cost base [45] Question: Why was CapEx for 2025 below initial guidance despite higher openings? - The company optimized capital spending while maintaining the planned number of openings, benefiting from localized suppliers and reduced per unit costs [47][48] Question: Are there signs of same-store sales recovery in the first quarter of 2026? - The company plans to deliver comparable sales growth in line with inflation levels, supported by a robust marketing plan [51]

Financial Data and Key Metrics Changes - In Q4 2025, Uniti reported a year-over-year revenue growth of 13% in its core Fiber business [6] - Kinetic added 28,000 net fiber subscribers, the highest in almost three years, with total Kinetic fiber subscribers growing 20% year-over-year [18] - Consolidated pro forma revenue was down approximately 5% year-over-year, primarily due to declines in legacy services [22] Business Line Data and Key Metrics Changes - Kinetic expanded its fiber network to pass an additional 80,000 homes, ending the year with approximately 1.9 million homes passed with fiber [18] - Kinetic consumer fiber revenue grew 24% year-over-year during the quarter [18] - Fiber Infrastructure recorded consolidated bookings MRR of approximately $1.7 million, tying the highest level on record [19] Market Data and Key Metrics Changes - Fiber penetration at Kinetic reached 29%, up 30 basis points sequentially and 150 basis points year-over-year [19] - Fiber ARPU increased by 5% year-over-year, indicating a positive trend [19] Company Strategy and Development Direction - Uniti aims to ramp up its fiber to the home build at Kinetic, targeting 450,000-500,000 new homes in 2026 [8] - The company is focused on transforming Kinetic into an insurgent fiber provider, moving away from traditional telecom operations [11] - Uniti plans to build approximately 6,000 new route miles of fiber over the next three years, expecting significant non-recurring cash revenue [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving consolidated revenue and EBITDA growth in 2027, despite potential bumps along the way [10] - The company is well-positioned to capture opportunities in wholesale fiber, particularly driven by AI and hyperscaler demand [13] - Management noted that 2026 is a critical investment year, with a focus on operational excellence and customer satisfaction [12] Other Important Information - Uniti has successfully lowered its cost of capital through landmark ABS transactions [5] - The company is evaluating its portfolio for optimization, identifying $500 million-$1 billion of non-core assets that could be monetized [32] Q&A Session Summary Question: Can you help us with the mechanics of the 22% IRRs for Anchor? - Management explained that high returns are partly due to selling existing infrastructure and leveraging greenfield builds [35][37] Question: What is the cadence of the $1 billion non-recurring revenue expected from now to 2028? - Management indicated that revenue will build over the next 2-3 years, with some deals taking longer to deploy [42] Question: Do you have concerns about labor or material availability for the expanded fiber build? - Management expressed confidence in resource availability, relying on trusted third-party relationships for fiber builds [46][47] Question: What is your exposure to EchoStar's lease cancellations? - Management stated that revenue exposure to DISH is less than 1%, deeming it immaterial [51] Question: How much of the $1.5 billion hyperscale opportunity do you expect to win? - Management indicated a good percentage of the funnel is contracted, with ongoing visibility into future deals [55][58] Question: What is your overall ARPU strategy going forward? - Management outlined a strategy focused on inflationary price increases, upgrading customer speeds, and selling value-added services [63][66]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported GAAP net income of $0.14 per share and adjusted distributable earnings (ADE) of $0.47 per share, exceeding dividends of $0.39 per share [4][12] - The economic return for the fourth quarter was 4.6% annualized, with book value per share at $13.16 [19][40] - The weighted average borrowing rate on recourse borrowings decreased by 32 basis points to 5.67% [16] Business Line Data and Key Metrics Changes - The credit portfolio saw net interest income increase sequentially, with contributions from non-QM retained tranches and forward MSR-related investments [12][13] - The Longbridge segment reported strong origination profits driven by higher origination volumes and margins, alongside positive contributions from servicing [13][14] - The adjusted long credit portfolio increased by 15% to $4.1 billion quarter-over-quarter, with growth in non-QM loans, agency-eligible loans, and commercial mortgage bridge loans [14][15] Market Data and Key Metrics Changes - The agency-eligible loan strategy added approximately $250 million in loans during the second half of 2025, reflecting a shift towards sectors where GSEs are reducing their footprint [8][9] - The company completed seven securitizations in Q4 2025, expanding its securitization platform to include various loan types [20][21] - The total long agency RMBS portfolio decreased slightly to $218 million, while the Longbridge portfolio decreased by 18% to $617 million due to securitizations [15] Company Strategy and Development Direction - The company aims to optimize its capital structure and enhance balance sheet resilience by increasing the proportion of long-term, non-mark-to-market borrowings [10][18] - The focus is on growing loan origination market share while maintaining strong credit performance, supported by a robust securitization platform [38] - The company is in contract to acquire a small residential mortgage servicer to enhance in-house servicing capabilities, particularly for delinquent assets [36] Management's Comments on Operating Environment and Future Outlook - Management noted that the housing market shows broader signs of weakness, with more borrowers struggling to stay current, but they maintain significant credit hedges [27] - The company is optimistic about the long-term opportunities in the agency-eligible sector, especially as policymakers are more receptive to private capital [9] - The economic environment remains uncertain, with potential government policy changes impacting the mortgage market [24][66] Other Important Information - The company completed 25 securitizations in 2025, significantly up from seven in 2024, indicating a strong focus on enhancing its funding profile [29] - The company has maintained low realized credit losses, reflecting strong underwriting discipline and asset management capabilities [30] Q&A Session Summary Question: Discussion on the decision to buy the servicer - Management highlighted the consolidation in the servicing industry and the need for best-in-class protocols to handle borrowers facing challenges, emphasizing the importance of in-house capabilities [42][43] Question: Conditions for applying repo to retained tranches - Management noted that the repo market functioned well, with low financing spreads, but they prefer to operate conservatively and avoid adding more leverage to retained tranches due to inherent price volatility [53][55] Question: Approach to the agency-eligible market amid potential changes - Management indicated that while there are risks associated with potential changes in LLPAs and g-fees, current execution remains favorable for private label markets, and they are monitoring these developments closely [62][66] Question: Current competition and margins in origination activity - Management described the competitive landscape as challenging but not cutthroat, with margins remaining attractive due to favorable pricing structures [71][73]

Financial Data and Key Metrics Changes - Bausch Health reported a revenue of $2,796 million for Q4 2025, reflecting a 9% increase year-over-year on a reported basis [11] - Adjusted EBITDA for Q4 was $1,052 million, marking a 13% increase compared to the same quarter last year [11] - For the full year 2025, revenue grew by 7% on a reported basis and 6% on an organic basis [8] Business Line Data and Key Metrics Changes - Salix revenues in Q4 were $693 million, a 9% increase year-over-year [14] - Solta Medical segment revenues were $137 million, a slight decrease of 1% on a reported basis [16] - Diversified segment revenues increased by 12% to $255 million, primarily due to improved net pricing [17] Market Data and Key Metrics Changes - International segment revenues were $306 million, a 10% increase on a reported basis [15] - EMEA and LatAm markets showed double-digit growth, while Canada experienced a 6% contraction [15] - South Korea's revenue for Solta was up 40%, making it the largest revenue-generating geography for Solta in 2025 [16] Company Strategy and Development Direction - The company aims to enhance its operational assets through innovation and optimizing brand growth globally [23] - Bausch Health is focused on business development opportunities to expand its portfolio and maximize shareholder value [23] - The acquisition of Shibo's aesthetics business in China is expected to strengthen the company's market presence [8][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong performance across markets and improved capital structure [6][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance of $5.25 billion to $5.4 billion [21][22] - Management acknowledged the disappointment regarding the RED-C trial results but remains committed to exploring new development opportunities [10] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow and reduced net debt by approximately $320 million in Q4 [13][8] - A significant debt exchange improved the company's debt maturity profile by approximately $1.7 billion [8] Q&A Session Summary Question: What is the updated decision framework for the separation post RED-C readout? - Management stated there is no change in focus on debt repayment and reinvestment in the business despite disappointment in RED-C results [34] Question: Can you provide more details about business development plans? - Management is screening assets for potential acquisitions and leveraging their commercial team for growth opportunities [37][38] Question: What is the impact of higher-than-planned residual volume from Medicaid? - Most of the residual volume was associated with XIFAXAN, amounting to less than $50 million in revenue for Q4 [80] Question: What are the key events to watch regarding Xifaxan generics? - Management confirmed that a generic is expected in January 2028, with ongoing legal proceedings affecting exclusivity [86] Question: What is the expected EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would be around $2.7 billion, reflecting a dip compared to 2025 [88]

Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025 compared to Q4 2024, reaching $2,796 million, with adjusted EBITDA rising by 13% to $1,052 million [10][11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA by 10%, indicating strong operational performance [18][19] - Adjusted gross margin was 71.6%, down 80 basis points year-over-year, while adjusted operating expenses increased by $75 million to $1,033 million [10][11] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year, driven by strong demand and promotional efforts [12] - Solta Medical segment revenues decreased by 1% to $137 million, impacted by distributor transition in China, but would have shown mid-single-digit growth without this effect [15][16] - The diversified segment saw a 12% revenue increase to $255 million, primarily due to improved net pricing [16] Market Data and Key Metrics Changes - International segment revenues were $306 million, up 10% on a reported basis, with EMEA and LatAm showing double-digit growth, while Canada contracted by 6% [13][14] - The Latin American market returned to growth with a 22% revenue increase, while Canada faced challenges due to increased generic competition [14][15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally, with a focus on business development opportunities [21][22] - The acquisition of Shibo's aesthetics distribution platform in China is expected to strengthen the company's market presence and enhance direct engagement with providers [7][26] - Strategic priorities for 2026 include maximizing shareholder value and optimizing the capital structure following significant refinancing [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong cash generation and improved capital structure, allowing for proactive business development [5][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance range of $5.25 billion to $5.4 billion [20][21] - Management acknowledged the disappointment regarding the RED-C trial results but remains focused on advancing other development opportunities [9] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [7][12] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange, providing additional flexibility for future opportunities [7][19] Q&A Session Summary Question: Post RED-C readout, what is the updated decision framework for separation and debt repayments? - Management stated there is no change in focus, continuing to prioritize debt repayment and reinvestment in the business [33] Question: Can you provide more details about business development plans? - Management is screening various assets for potential acquisitions, leveraging their strong commercial team [36][37] Question: What is the impact of the Shibo integration on revenue and EBITDA growth? - The integration is progressing well, with a minor EBITDA impact of $10-$15 million due to accounting adjustments [45][47] Question: What are the expectations for Xifaxan generics? - Management confirmed that a generic is expected by January 1, 2028, and is focused on maximizing current value [84] Question: What is the EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would likely be around $2.7 billion, reflecting a dip compared to 2025 [86]

Core Viewpoint - PAVmed has successfully closed financings that eliminate all previously outstanding convertible securities, significantly strengthening its balance sheet and capital structure [1] Financing Details - The Series D Preferred Stock offering generated $30 million in gross proceeds, with warrants for an additional $30 million contingent on a positive Medicare local coverage determination for the EsoGuard test [1] - A new senior secured note with a three-year maturity raised an additional $15 million [1] - The total net cash proceeds from these transactions amount to approximately $7.7 million, which will be used for general working capital [1] Capital Structure Improvement - The proceeds from the financings were utilized to redeem all outstanding Series C Convertible Preferred Stock and fully retire existing convertible debt [1] - Assuming the exercise of associated warrants and conversion of Series D Preferred Stock, the company could achieve a clean capital structure consisting entirely of common stock and long-term debt, adding approximately $37.7 million in cash to the balance sheet [1] Strategic Positioning - PAVmed's Chairman and CEO highlighted that this transaction is a transformative outcome aimed at fixing the legacy capital structure and unlocking the company's asset strength for shareholders [1] - The company is now positioned to pursue additional commercial opportunities and enhance long-term shareholder value, leveraging its subsidiaries, including Lucid Diagnostics and Veris Health [1]

Core Viewpoint - Saudi Aramco has successfully completed a $4 billion bond issuance, demonstrating its ability to raise capital under favorable conditions despite global market volatility [1]. Group 1: Bond Issuance Details - The bond sale was structured into four tranches: $500 million in senior notes maturing in 2029 with a 4.0% coupon, $1.5 billion in 2031 notes at 4.375%, $1.25 billion in 2036 notes at 5.0%, and $750 million in long-dated 2056 notes with a 6.0% coupon [2]. - The transaction was priced on January 26 and the notes were listed on the London Stock Exchange [2]. Group 2: Investor Confidence and Pricing - Pricing included negative new issue premiums on three of the four tranches, indicating strong investor confidence in Aramco's balance sheet and credit profile [3]. - Such pricing is typically reserved for top-tier issuers, reflecting Aramco's status as one of the strongest credits in the global energy sector [3]. Group 3: Strategic Financial Management - The issuance aligns with Aramco's strategy to optimize its capital structure while maintaining strict financial discipline, supporting long-term shareholder value creation [4]. - Accessing long-dated capital at competitive rates provides financial flexibility for Aramco while preserving cash flows for dividends and strategic projects [5]. Group 4: Market Position and Historical Context - Aramco has been a regular issuer in international debt markets since its debut global bond sale in 2019, primarily using proceeds for general corporate purposes and balance sheet management [6]. - The company benefits from substantial hydrocarbon reserves, low production costs, and strong ties to the Saudi state, which support its robust credit metrics [6]. Group 5: Investor Demand and Market Trends - The successful bond placement signals ongoing investor demand for high-quality energy credits, despite energy transition risks and oil price volatility [7]. - For sovereign-linked producers with scale and financial strength, debt markets remain an attractive tool for capital management [7].

Core Insights - BV Financial, Inc. reported a significant increase in net income for the fourth quarter of 2025, reaching 56 cents per share compared to 18 cents per share in the same period last year [1] - The company's stock has seen a decline of 2% since the earnings report, contrasting with a 0.9% increase in the S&P 500 index during the same timeframe [1] Financial Performance - Net income more than doubled year-over-year to $4.8 million from $2 million, with non-GAAP adjusted net income rising to $5.6 million from $2.4 million [2] - Full-year net income was reported at $13.5 million, or $1.43 per share, up from $11.7 million, or $1.10 per share in 2024 [2] - Adjusted net income grew to $16.3 million from $12.9 million, reflecting adjustments for expenses related to the 2024 Equity Incentive Plan [2] Key Business Metrics - Total assets as of December 31, 2025, were $912.2 million, a slight increase from $911.8 million the previous year [3] - Net loans increased by $19.2 million, or 2.6%, to $748.5 million, with growth in specific loan categories offsetting declines in others [3] Deposits and Debt Management - Total deposits rose by $24.6 million, or 3.8%, to $676.1 million, driven by a 6.7% increase in non-interest-bearing deposits [4] - The company repaid $35 million in subordinated debt, replacing it with lower-cost Federal Home Loan Bank advances [4] Shareholder Value Initiatives - BV Financial executed a stock buyback program, repurchasing 1.8 million shares during 2025 at an average price of $16.23, including 714,555 shares in the fourth quarter [4] Efficiency and Returns - Return on average assets (ROAA) improved to 2.1% from 0.9% year-over-year, while return on average equity (ROAE) surged to 10.5% from 3.8% [5] - The efficiency ratio improved to 51% in the fourth quarter from 64.3% in the prior-year period, indicating stronger operating leverage [5] Strategic Management Decisions - The company's strategic focus includes optimizing its capital structure and cost management, as evidenced by the replacement of subordinated debt and the share repurchase program [6] Earnings Drivers - A key contributor to the earnings upside was a $1.9 million recovery in provision for credit losses in the fourth quarter, reversing a provision of $0.6 million in the year-ago period [7] - Net interest income rose 8.2% year-over-year in the quarter to $9.8 million, driven by a higher net interest margin of 4.52%, up from 4.34% [8] Noninterest Income and Expenses - Noninterest income saw a modest increase to $0.8 million in the quarter from $0.6 million a year earlier [9] - Noninterest expense declined 13.4% year-over-year to $5.4 million, largely due to a drop in compensation and benefits expenses [9] Balance Sheet Maneuvers - The company retired its $35 million subordinated debt issued in 2020, replacing it with lower-cost Federal Home Loan Bank borrowings, expected to reduce interest expense going forward [10]

Core Viewpoint - Trinity Biotech plc has entered into agreements with Perceptive Advisors to enhance its financial flexibility and optimize its capital structure, supporting ongoing and future growth projects [1][2]. Financial Capacity and Operational Flexibility - The transactions strengthen Trinity Biotech's financial capacity and operational flexibility, enabling continued investment in strategic growth priorities and reinforcing its ability to deliver advanced diagnostic and diabetes management solutions [2][3]. - The agreements position Trinity Biotech to advance its long-term growth agenda while supporting a reduction in overall debt levels [2]. Overview of the Transactions - The agreements reflect a positive relationship between Trinity Biotech and Perceptive Advisors, underscoring their support for the Company's strategy and operational momentum [3]. Financial Summary - The Second Amendment to the Credit Agreement extends the maturity to early 2027 and provides increased near-term funding [6]. - New term-loan proceeds of $5 million will strengthen liquidity for key strategic development initiatives, including the continuous glucose monitoring solution, CGM+ [7]. - Up to $60 million in elective equitization capacity under the term-loan may allow for significant debt and cash interest cost reductions [7]. - Equity settlement mechanisms for milestone payments and contingent obligations are designed to reduce cash requirements [7]. Management Commentary - The CEO of Trinity Biotech stated that these developments place the company in a stronger strategic position to accelerate its innovation agenda, particularly in diabetes management and diagnostics [8].

Core Viewpoint - Nuvini Group Limited has successfully renegotiated earnout contingent liabilities with founders of previously acquired companies, resulting in a 36% reduction in these obligations, which significantly improves its capital structure and debt profile [1][2]. Capital Structure Improvement - The restructuring enhances Nuvini's proforma debt-to-EBITDA ratio, positioning the company to secure more favorable terms for private credit financing [2]. - This improved capital structure will facilitate the payoff of existing obligations and fund new strategic acquisitions within the next 90 days [2]. Strategic Rationale - The restructuring reflects the company's commitment to maintaining a disciplined and optimized capital structure while executing its acquisition strategy [3]. - By renegotiating earnout obligations, Nuvini has created significant financial flexibility, enabling access to private credit markets on more attractive terms [3]. - The renegotiation highlights the strong relationships Nuvini maintains with founders across its portfolio, aligning all parties on long-term value creation opportunities [3]. M&A Pipeline Update - Nuvini is advancing its strategic acquisition agenda and is on track to close the acquisition of MK Solutions, a leading ERP for ISPs [4]. - The company has a robust pipeline of negotiated acquisition targets that meet its disciplined investment criteria [4]. Future Growth Strategy - The company believes it is prudent to optimize its capital structure before pursuing additional transactions, which positions it to execute more efficiently and on better terms as it aims for growth objectives [5].